Fitch K, Ferro C, Pittinger S. The cost burden of blood cancer care in Medicare A longitudinal analysis of Medicare Advantage and Fee for Service patients diagnosed with blood cancer. Published online 2019.

Dieguez G, Ferro C, Rotter D. The cost burden of blood cancer care: a longitudinal analysis of commercially insured patients diagnosed with blood cancer. 2018.

Kent EE, Forsythe LP, Yabroff KR, et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer. 2013;119(20):3710–7. https://doi.org/10.1002/CNCR.28262.

Article  PubMed  Google Scholar 

Knight TG, Deal AM, Dusetzina SB, et al. Financial toxicity in adults with cancer: adverse outcomes and noncompliance. J Oncol Pract. 2018;14(11) https://doi.org/10.1200/JOP.18.00120.

Huntington SF, Weiss BM, Vogl DT, et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol. 2015;2(10):e408–16. https://doi.org/10.1016/S2352-3026(15)00151-9.

Article  PubMed  Google Scholar 

Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34(9):980–6. https://doi.org/10.1200/JCO.2015.64.6620.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma SJ, Iovoli AJ, Attwood K, et al. Association of significant financial burden with survival for head and neck cancer patients treated with radiation therapy. Oral Oncol. 2021:115. https://doi.org/10.1016/J.ORALONCOLOGY.2021.105196.

Chino F, Zafar SY. Financial toxicity and equitable access to clinical trials. Am Soc Clin Oncol Educ Book. 2019;39(39):11–8. https://doi.org/10.1200/EDBK_100019.

Article  PubMed  Google Scholar 

Nipp RD, Lee H, Gorton E, et al. Addressing the financial burden of cancer clinical trial participation: longitudinal effects of an equity intervention. Oncologist. 2019;24(8):1048–55. https://doi.org/10.1634/THEONCOLOGIST.2019-0146.

Article  PubMed  PubMed Central  Google Scholar 

Pak TY, Kim H, Kim KT. The long-term effects of cancer survivorship on household assets. Health. Econ Rev. 2020;10(1) https://doi.org/10.1186/S13561-019-0253-7.

Doroudi M, Coughlan D, Banegas MP, Han X, Robin YK. Is cancer history associated with assets, debt, and net worth in the United States? JNCI Cancer Spectr. 2018;2(2) https://doi.org/10.1093/JNCICS/PKY004.

Ramsey S, Blough D, Kirchhoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013;32(6):1143–52. https://doi.org/10.1377/HLTHAFF.2012.1263.

Article  PubMed  PubMed Central  Google Scholar 

Mehnert A, De Boer A, Feuerstein M. Employment challenges for cancer survivors. Cancer. 2013;119(SUPPL11):2151–9. https://doi.org/10.1002/CNCR.28067.

Article  PubMed  Google Scholar 

Smith GL, Banegas MP, Acquati C, et al. Navigating financial toxicity in patients with cancer: a multidisciplinary management approach. CA Cancer J Clin. 2022;72(5):437–53. https://doi.org/10.3322/caac.21730.

Article  PubMed  Google Scholar 

Preussler JM, Meyer CL, Mau LW, et al. Healthcare costs and utilization for patients age 50 to 64 years with acute myeloid leukemia treated with chemotherapy or with chemotherapy and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23(6):1021–8. https://doi.org/10.1016/J.BBMT.2017.02.017.

Article  PubMed  PubMed Central  Google Scholar 

Zhu F, Wei G, Zhang M, et al. Cell Transplant. 2020:29. https://doi.org/10.1177/0963689720919434.

Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. 2003;348(19):1875–83. https://doi.org/10.1056/NEJMOA022340.

Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349–61. https://doi.org/10.1001/JAMA.2009.813.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transplant. 2016;51(4):521–8. https://doi.org/10.1038/BMT.2015.332.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009;27(23):3868–74. https://doi.org/10.1200/JCO.2009.23.1183.

Article  PubMed  Google Scholar 

Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist. 2013;18(4):381–90. https://doi.org/10.1634/THEONCOLOGIST.2012-0279.

Article  PubMed  PubMed Central  Google Scholar 

Lentz R, Benson AB, Kircher S. Financial toxicity in cancer care: prevalence, causes, consequences, and reduction strategies. J Surg Oncol. 2019;120(1):85–92. https://doi.org/10.1002/JSO.25374.

Article  PubMed  Google Scholar 

Ouchveridze E, Banerjee R, Desai A, et al. Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J. 2022;12(4). https://doi.org/10.1038/S41408-022-00671-Z.

Su CT. Financial toxicity interventions in hematologic malignancies are timely and necessary. JCO Oncol Pract. 2022;18(9):607–9. https://doi.org/10.1200/op.22.00357.

Article  PubMed  Google Scholar 

Su CT, Shankaran V. Defining the role of the modern oncology provider in mitigating financial toxicity. J Am Coll Radiol. 2022. https://doi.org/10.1016/j.jacr.2022.10.011.

Raghavan D, Keith NA, Warden HR, et al. Levine Cancer Institute Financial Toxicity Tumor Board: a potential solution to an emerging problem. JCO Oncol Pract. 2021;17(10):e1433–9. https://doi.org/10.1200/op.21.00124.

Article  PubMed  PubMed Central  Google Scholar 

de Souza JA, Yap BJ, Wroblewski K, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017;123(3):476–84. https://doi.org/10.1002/CNCR.30369.

Article  PubMed  Google Scholar 

De Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer. 2014;120(20):3245–53. https://doi.org/10.1002/CNCR.28814.

Article  PubMed  Google Scholar 

Chino F, Peppercorn JM, Rushing C, et al. Out-of-pocket costs, financial distress, and underinsurance in cancer care. JAMA Oncol. 2017;3(11):1582–4. https://doi.org/10.1001/JAMAONCOL.2017.2148.

Article  PubMed  PubMed Central  Google Scholar 

Knight TG, Aguiar M, Robinson M, et al. Financial toxicity intervention improves outcomes in patients with hematologic malignancy. JCO Oncol Pract. 2022;18(9):e1494–504. https://doi.org/10.1200/op.22.00056.

Article  PubMed  Google Scholar 

Pelcovits A, Niroula R. Acute myeloid leukemia: a review. R I Med J (2013). 2020;103(3):38-40. http://www.ncbi.nlm.nih.gov/pubmed/32236160 . Accessed 3/19/2023

Litzow MR, Ferrando AA. How I treat T-cell acute lymphoblastic leukemia in adults. Blood. 2015;126(7):833–41. https://doi.org/10.1182/blood-2014-10-551895.

Article  CAS  PubMed  Google Scholar 

Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(February):v69–82. https://doi.org/10.1093/annonc/mdw025.

Article  CAS  PubMed  Google Scholar 

Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306–11. https://doi.org/10.1200/JCO.2013.52.9123.

Article  PubMed  Google Scholar 

Jain AG, Elmariah H. BMT for myelodysplastic syndrome: when and where and how. Front Oncol. 2022;11(January):1–13. https://doi.org/10.3389/fonc.2021.771614.

Article  CAS  Google Scholar 

Fenaux P, Platzbecker U, Ades L. How we manage adults with myelodysplastic syndrome. Br J Haematol. 2020;189(6):1016–27. https://doi.org/10.1111/bjh.16206.

Article  CAS  PubMed  Google Scholar 

Knight TG, Robinson M, Ai J, et al. Patient reported financial toxicity in myeloproliferative neoplasms. Blood. 2019;134(Supplement_1):2099. https://doi.org/10.1182/BLOOD-2019-128858.

Article  Google Scholar 

Sehn LH, Salles G. Diffuse large B-cell lymphoma. Longo DL, ed. N Engl J Med. 2021;384(9):842-858. doi:https://doi.org/10.1056/NEJMRA2027612.

Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95(3):316–27. https://doi.org/10.1002/AJH.25696.

Article  CAS  PubMed  Google Scholar 

Ansell SM. Hodgkin lymphoma: a 2020 update on diagnosis, risk-stratification, and management. Am J Hematol. 2020;95(8):978–89. https://doi.org/10.1002/AJH.25856.

Article  PubMed  Google Scholar 

Morrison VA, Bell JA, Hamilton L, et al. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA. Future Oncol. 2018;14(25):2627–42. https://doi.org/10.2217/FON-2018-0267.

Article  CAS  PubMed  Google Scholar 

Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9) https://doi.org/10.1038/s41408-020-00359-2.

Goodwin JA, Coleman EA, Sullivan E, et al. Personal financial effects of multiple myeloma and its treatment. Cancer Nurs. 2013;36(4):301–8. https://doi.org/10.1097/NCC.0b013e3182693522.

Article  PubMed  PubMed Central  Google Scholar 

Fiala MA, Silberstein AE, Schroeder MA, Stockerl-Goldstein KE, Vij R. The dynamics of financial toxicity in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023:1–7. https://doi.org/10.1016/j.clml.2023.01.008.

Cusatis R, Tan I, Piehowski C, et al. Worsening financial toxicity among patients receiving chimeric antigen receptor t-cell (CAR-T) therapy: a mixed methods longitudinal study. Blood. 2021;138(Supplement 1):567. https://doi.org/10.1182/BLOOD-2021-146032.

Article  Google Scholar 

Hay AE, Cheung MC. CAR T-cells: costs, comparisons, and commentary. J Med Econ. 2019;22(7):613–5. https://doi.org/10.1080/13696998.2019.1582059.

Article  PubMed  Google Scholar 

Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34–48. https://doi.org/10.1016/j.annonc.2020.10.478.

Article  CAS  PubMed  Google Scholar 

Baum LV, Koyama T, Schremp EA, et al. Posttraumatic stress symptoms and financial toxicity among adolescent and young adult oncology patients and their caregivers at cancer diagnosis. Cancer. 2022;128(10):2005–14. https://doi.org/10.1002/cncr.34146.

Article  PubMed  Google Scholar 

Edward JS, Mclouth LE, Rayens MK, Eisele LP, Davis TS. Coverage and cost-of-care links: addressing financial toxicity among